Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion.Martin J. van den Bent, Pim J. French, Paul M. Clément et al.|Journal of Clinical Oncology|2019Cited by 48
ACTR-11. SECOND INTERIM AND 1ST MOLECULAR ANALYSIS OF THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON TRIAL ON CONCURRENT AND ADJUVANT TEMOZOLOMIDE IN ANAPLASTIC GLIOMA WITHOUT 1p/19q CODELETIONMartin J. van den Bent, Pim J. French, Sara Erridge et al.|Neuro-Oncology|2019Cited by 6
Final clinical and molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion: NCT00626990.Martin J. van den Bent, Sara Erridge, Michael A. Vogelbaum et al.|Journal of Clinical Oncology|2025Cited by 5
BIOM-09. PROGNOSTIC AND PREDICTIVE MARKERS FOR OUTCOME IN PATIENTS WITH IDHMT TUMORS TREATED IN THE EORTC CATNON TRIAL ON ADJUVANT AND/OR CONCURRENT TEMOZOLOMIDE IN ANAPLASTIC ASTROCYTOMAMartin J. van den Bent, Pim J. French, Santoesha Ghisai et al.|Neuro-Oncology|2025Cited by 1